Table 2.
SYNERGY data collection schedule
| |
Run-in Week −2 |
Intervention A & B |
|||
|---|---|---|---|---|---|
|
Baseline |
Mid point |
End point |
|||
| Week 0 & 11 | Week 3 & 14 | Week 6 & 17 | |||
|
Serum uremic toxins |
Indoxyl sulphate (free and total) |
X |
X |
X |
X |
| P-cresyl sulphate (free and total) |
X |
X |
X |
X |
|
|
Cardiovascular risk |
Oxidative stress |
|
X |
|
X |
| Inflammation |
|
X |
|
X |
|
| |
Endotoxemia (lipopolysaccharide) |
|
X |
|
X |
|
Kidney damage |
24 hr albuminuria and protienuria |
|
X |
|
X |
| Kidney injury molecule-1 |
|
X |
|
X |
|
| |
Estimated glomerular filtration rate |
X |
X |
|
X |
|
Dietary |
Diet history interview |
X |
|
|
X |
| 24 hr recall |
|
X |
X |
|
|
| |
24 hr urinary urea nitrogen |
|
X |
|
X |
|
Quality of life |
Short Form-36 |
|
|
|
X |
|
Gastrointestinal symptoms |
Gastrointestinal symptom rating scale |
X |
|
X |
X |
|
Gut microbiota |
Fecal sample (optional) |
|
X |
|
X |
|
Compliance |
Pill count |
|
|
X |
X |
| Dose escalation | X | ||||